Rituximab: a safe therapeutic option during the COVID-19 pandemic?

Di Altobrando, Ambra; Patrizi, Annalisa; Abbenante, Diego; Bardazzi, Federico

Di Altobrando, Ambra; Patrizi, Annalisa; Abbenante, Diego; Bardazzi, Federico.

Di Altobrando A; Department of Experimental, Diagnostic and Specialty Medicine - Division of Dermatology, University of Bologna, Bologna, Italy.
Patrizi A; Department of Experimental, Diagnostic and Specialty Medicine - Division of Dermatology, University of Bologna, Bologna, Italy.
Abbenante D; Department of Experimental, Diagnostic and Specialty Medicine - Division of Dermatology, University of Bologna, Bologna, Italy.
Bardazzi F; Department of Experimental, Diagnostic and Specialty Medicine - Division of Dermatology, University of Bologna, Bologna, Italy.

J Dermatolog Treat ; 33(2): 1197, 2022 03.

Article in English | MEDLINE | ID: covidwho-1778772

Subject(s)

COVID-19; Humans; Immunologic Factors/adverse effects; Pandemics; Rituximab/therapeutic use; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: English Journal: J Dermatolog Treat Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: 09546634.2020.1800565

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google